Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a drop in COVID-19 vaccine sales.
Net income decreased by 70% to $1.5 billion while EPS dropped by 68% to $3.61 compared to the same period last year.
The company expects product sales of approx. $2 billion in the first half of 2023.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
NFLX Earnings: Netflix Q1 2025 revenue and profit beat estimates
Netflix, Inc. (NASDAQ: NFLX) on Thursday reported stronger-than-expected revenue and earnings for the first quarter of 2025, as its subscriber base continued to expand. Both revenue and the bottom line
Another tough quarter in the cards as Intel prepares for Q1 2025 earnings
Intel Corporation (NASDAQ: INTC) has been facing intense competition from rivals Nvidia in AI chips and AMD in CPUs, lately. The Semiconductor giant issued weak guidance after reporting lower revenues
What to expect when American Airlines (AAL) reports Q1 2025 earnings results
Shares of American Airlines Group (NASDAQ: AAL) stayed red on Thursday. The stock has dropped 48% over the past three months. The airline is slated to report its earnings results
